Several mutations in the Human Ether-a-go-go-Related K + channel Gene (HERG or KCNH2) cause long QT syndrome (LQT2) by reducing the intracellular transport (trafficking) of the channel protein to the cell surface. Drugs that bind to and block HERG channels (i.e. E4031) rescue the surface expression of some trafficking-defective LQT2 mutations. Since these drugs potently block HERG current, their ability to correct congenital LQT is confounded by their risk of causing acquired LQT. We tested the hypothesis that pharmacological rescue can occur without HERG channel block. Thapsigargin (1µM), a sarcoplasmic/endoplasmic reticulum Ca 2+ -ATPase inhibitor, rescued the surface expression of G601S, and it did so without blocking current. Thapsigargin-induced rescue and E4031-induced rescue caused complex glycosylation that was evident within three hours of drug exposure. Disruption of the Golgi apparatus with Brefeldin A prevented thapsigargin-and E4031-induced rescue of I G01S . Confocal imaging showed that G601S protein is predominantly "trapped" intracellularly, and that both thapsigargin and E4031 promote its relocation to the surface membrane. We also studied two other trafficking-defective LQT2 mutations. Thapsigargin rescued the C-terminus mutation F805C but not N470D, whereas E4031 rescued N470D but not F805C. Other sarcoplasmic/endoplasmic reticulum Ca 2+ -ATPase inhibitor inhibitors did not rescue G601S or F805C. This study, 1) supports the hypothesis that the LQT2 trafficking-defective phenotype can be reversed without blocking the channel, 2) demonstrates pharmacological rescue of a C-terminus LQT2 mutation, and 3) shows that thapsigargin can correct trafficking defective phenotypes in more than one channel type and disease (i.e., LQT2 and cystic fibrosis).
Introduction
Mutations in the Human Ether-a-go-go-Related Gene (HERG or KCNH2) K + channel cause long QT syndrome 1 (LQT2) by reducing functional HERG current (I HERG ).
Several LQT2 mutations disrupt ion channel transport (trafficking) out of the endoplasmic reticulum (ER) (1) . The surface membrane expression in some of these trafficking-defective LQT2 mutations can be increased (rescued) in cells expressing mutant channels by reducing cell culture temperature (<30 o C) and/or incubating in drugs that cause high affinity HERG channel block (2, 3, 4, 5, 6) . The rescue of traffickingdefective LQT2 channels can increase functional I HERG , and therefore has therapeutic potential.
Amino acid residues on the inner portion of the 6 th transmembrane segment (S6)
of HERG channel protein constitute a binding domain for drugs that cause high affinity I HERG block, and this binding domain is also thought to mediate pharmacological rescue of trafficking-defective LQT2 mutations by high affinity HERG blockers (5, 7, 8) . For most drugs, block of I HERG occurs at concentrations below that required for the rescue of mutant channels (3, 5 , but see 9). Therefore, using drugs that cause high affinity HERG channel block as a means of restoring protein trafficking negates their therapeutic potential.
We tested the hypothesis that we could pharmacologically rescue traffickingdefective LQT2 channels without using drugs that block I HERG . Our approach has similarity to cystic fibrosis, where the predominant mutation, ∆F508 (deletion of Page 4/r1 experimental drugs rescue surface membrane expression of ∆F508 CFTR without blocking the channel (for review, see 11). In recent animal and human trials drugs such as thapsigargin (12) and sodium 4-phenylbuterate (4-PBA, 13) are hypothesized to rescue ∆F508 CFTR expression by altering its interaction(s) with molecular chaperone proteins (12, 15, 16 , see also editorial 17). We speculated that if similar molecular chaperone proteins regulated LQT2 trafficking-defective mutations, then these drugs might cause the pharmacological rescue in some LQT2 mutations without blocking I HERG . We first studied the mechanism of pharmacological rescue using the G601S LQT2 mutation, and then compared these findings with two additional LQT2 mutations, N470D and F805C.
Experimental Procedures

Cell Lines and Drug Exposure
Human Embryonic Kidney 293 (HEK293) cell lines stably expressing WT HERG and the trafficking-defective LQT2 mutations N470D (asparagine to aspartate at amino acid position 470; 18), G601S (glycine to serine at position 601; 19) , and F805C
(phenylalanine to cysteine at position 805; 20) has been previously described (1, 2, 9) .
The cells are cultured in DMEM at 37 o C. Tunicamycin (Sigma-Aldrich, St.Louis, MO),
Page 5/r1 effect on I HERG or complex glycosylation. E4031 (Eisai, Ltd., Tokoyo, Japan) was added to the DMEM after being dissolved in distilled H 2 O to make a 10mM stock solution.
Electrophysiology
Functional analysis was done using standard whole-cell patch clamp technique as previously described (21) . Ionic currents were measured using an external solution that contained (in mM) 137 NaCl, G601S. We incubated HEK293 cells expressing G601S in 1µM thapsigargin for 8-10
hours and we compared G601S current (I G601S ) to control (no drug treatment) current. Figure 1A shows representative whole-cell currents with the voltage protocol shown in the inset. In control conditions there is only a low amplitude tail I G601S (left panels).
After 8-10 hours of incubation in 1µM thapsigargin, I G601S during the depolarizing and hyperpolarizing (-120 mV) steps was increased (right panels). The tail I G601S is shown in the lower panels on an expanded time base. Figure 1B shows the absolute mean peak tail thapsigargin for 10 hours (right lane). E4031 and thapsigargin caused the appearance of the 155kD protein band, although thapsigargin's effect was less robust. The appearance of the 155kD band is commonly used as an indicator of channel rescue (3, 5, 6) . Figure 2A shows the time-course of I G601S rescue with thapsigargin after 2-3 hours and 8-10 hours of exposure. Cells expressing G601S were depolarized for 3 seconds to 20mV to fully activate I G601S and tail currents were recorded at -120mV. Representative tail I G601S from control cells and from cells exposed to 1µM thapsigargin show a progressive, time dependent increase in the tail I G601S amplitude. Figure 2B shows the absolute mean peak tail I G601S density from control cells and cells incubated in thapsigargin. After incubating 2-3 hours, thapsigargin increased I G601S density (n=5 cells in each group, p<0.05), which was further increased after 8-10 hours. I G601S did not increase further after 8-10 hours of exposure. Figure 2C shows that incubating in 1µM thapsigargin or 5µM E4031 for 3 hours, compared with control conditions, was sufficient to cause the appearance of the 155kD protein band on Western blots.
Thapsigargin Does Not Block I G601S
We wanted to determine if thapsigargin rescue of G601S protein involved drug block of the channel. We first pharmacologically rescued I G601S by incubating G601S expressing cells overnight with 5µM E4031. Following this, cell culture media was replaced with E4031-free media for 1-2 hours before cells were harvested for patch clamp recording (3) . From the holding potential of -80 mV, I G601S was recorded by depolarizing cells to 0 mV for 3 seconds, then repolarizing to -50 mV for 5 seconds to record tail current. The voltage protocol was repeated every 20 seconds, and I G601S was recorded before and during the application of 1µM thapsigargin or 5µM E4031. Figure   3A shows representative current traces of pharmacologically rescued I G601S before and by guest on January 28, 2018
http://www.jbc.org/ during the application of 1µM thapsigargin (upper panel) or 5µM E4031 (lower panel).
Thapsigargin, unlike E4031, did not cause block of I G601S . Figure 3B shows averaged normalized peak tail I G601S amplitude data recorded at -50 mV from G601S expressing cells, and the effect of thapsigargin or E4031. Thapsigargin did not affect the peak tail I G601S (circles). In contrast, 5µM E4031 rapidly blocked I G601S (triangles). We conclude that thapsigargin-induced pharmacological rescue of G601S does not involve drug block of I HERG .
Pharmacological Rescue of G601S Protein Requires the Golgi Apparatus
Thapsigargin and E4031 rescue I G601S and cause complex glycosylation of the thapsigargin or 5µM E4031 for 2-3 hours to induce pharmacological rescue of the channel. As shown in Figure 2 , this incubation period is sufficient to rescue G601S channels. Thirty minutes after adding thapsigargin or E4031, 5µg/mL of BFA was added to some of the cell culture dishes. Figure 4A shows representative tail I G601S recorded at -120 mV from cells cultured with and without BFA, and Figure 4B shows the absolute mean peak tail I G601S density (n=4 cell in each group). BFA reduced I G601S rescue in cells exposed to thapsigargin or E4031 (p<0.05 in each group). For comparison, we incubated cells expressing WT HERG channels with 5µg/mL BFA. BFA exposure for 3 hours did not affect I HERG ; control peak tail I HERG was 157±20pA/pF (n=6 cells) and after BFA exposure for 2-3 hours peak tail I HERG was 168±21pA/pF (n=8 cells). Since co-incubating BFA inhibited the increase of I G601S by either thapsigargin or E4031 exposure, the data suggest that pharmacological rescue is dependent on an intact Golgi apparatus.
Pharmacological Rescue Redistributes Intracellular G601S Protein to the Cell Surface
The results suggest that incubation in thapsigargin or E4031 mobilizes G601S
protein that is present in an intracellular compartment(s). To test this, we used confocal microscopy to image G601S protein in control cells, and in cells incubated for 10 hours with 1µM thapsigargin or 5µM E4031 to induce pharmacological rescue. 
Thapsigargin and E4031 selectively rescue different LQT2 mutations
Three methods to increase functional I G601S are reduced culture temperature (<30 o C, 2), and incubating cells in high affinity HERG blockers or thapsigargin. We compared findings obtained with the G601S mutation with two other traffickingdefective LQT2 mutations. Figure 6A shows representative tail currents recorded at120mV from cells stably expressing the G601S, F805C, or N470D mutations under control conditions; after incubationg at 27 o C for 24 hours; and after incubating in thapsigargin (1µM) or E4031 (5µM) for 24 hours. Figure 6B shows that the absolute mean peak tail current density increased in all three LQT2 mutations after cell incubation at 27 o C (see also, 3, 5). In contrast, E4031 selectively increased peak tail I G601S and I N470D
densities, but not I F805C density. Incubating cells in thapsigargin for 24 hours selectively increased peak tail I G601S and I F805C densities, but not I N470D density (n=5-8 cells in each group). Figure 6C shows corresponding western blots from cells stably expressing each mutation for control conditions; after incubating cells at 27 o C for 24 hours; and after cells were exposed to either thapsigargin or E4031 at 37 o C for 24 hours. Complex glycosylation (the presence of the 155kD protein band) was minimal or absent for control conditions, but was apparent for all three mutations incubated at 27 o C. Complex glycosylation was apparent only in N470D and G601S after incubation in E4031, and only in G601S and F805C after incubation in thapsigargin. These data demonstrate that the presence of the 155kD band correlates with increased I HERG shown in panels A and B.
These data also show mutation-specific, selective pharmacological rescue, and demonstrate pharmacological rescue of a C-terminus trafficking defective LQT2 mutation.
Other SERCA inhibitors do not rescue G601S or F805C
We tested whether a different SERCA inhibitor could also rescue G601S or F805C by using 2,5-(di-tert)-butyl-1, 4-hydroquinone (DBHQ; 10µM). We measured peak tail current using the same voltage clamp protocol in Figure 2 . In control cells (n=5) and for cells incubated with 10µM DBHQ (n=4) for 8-10 hours the mean peak tail I G601S density remained unchanged, 8±2pA/pF. DBHQ exposure for 8-10 hours also failed to increase trafficking of F805C. The mean peak tail I F805C density in control cells was 30±6 pA/pF (n=7) and 27±3pA/pF (n=3) after exposure to DBHQ. Similarly, incubating G601S expressing cells in DBHQ (10µM) or cylcopiazonic acid (1 or 10µM),
another inhibitor of the SERCA, for 10 hours failed to cause complex glycosylation of G601S protein (data not shown, n=5 and n=2, respectively).
Thapsigargin rescues trafficking of ∆F508 CFTR (12), and to our knowledge our report is the first to show that a low concentration of a single drug can rescue the trafficking of mutant channel proteins found in different diseases. 4-PBA also rescues ∆F508 CFTR after 48 hours of exposure (14), therefore we tested if 4-PBA could increase G601S trafficking. 4-PBA (1mM or 10mM) incubation for 48 hours did not cause the appearance of the155kD protein band using western blot analysis (data not shown; n=2). We conclude that unlike thapsigargin, 4-PBA does not rescue trafficking of the G601S mutation, and this is in agreement with the previous report that 4-PBA did not rescue I N470D (9) .
Discussion
We show that thapsigargin causes pharmacological rescue of the LQT2 mutations G601S and F805C. This is the first study to show that thapsigargin can correct trafficking defective phenotypes in more than one channel type and disease (e.g., HERG and CFTR in LQT2 and cystic fibrosis). This is also the first study to show pharmacological rescue fexofenadine for 24 hours did not increase I F805C density (data not shown). We conclude that thapsigargin-induced pharmacological rescue is a mechanistically novel approach to increase the surface expression of some LQT2 trafficking-defective channels.
The Mechanism Of Thapsigargin-induced Rescue of G601S is Different than ∆F508
CFTR
The mechanism proposed for thapsigargin-induced pharmacological rescue of the ∆F508 CFTR mutation was SERCA inhibition, and finding that other SERCA inhibitors such as DBHQ and cylcopiazonic acid also rescued the trafficking of ∆F508 CFTR supported this (12) . These drugs deplete ER luminal [Ca 2+ ] and are thought to alter Ca 2+ -dependent molecular chaperone activity (for review, see 28). In the present work, we speculated that if similar molecular chaperone proteins regulated LQT2 traffickingdefective mutations, then these drugs might also cause the pharmacological rescue in some LQT2 mutations. Our findings suggest that the mechanism for thapsigargininduced rescue in LQT2 is different than that for ∆F508 in CFTR. The principal difference is that other SERCA inhibitors failed to rescue the G601S or F805C mutation.
Thus one possibility is that SERCA inhibition similar to that found with the ∆F508 CFTR mutation is not responsible for the rescue of G601S. Clearly, additional studies are needed to confirm this. Our findings do show that thapsigargin-induced rescue of G601S was evident within 2-3 hours of drug exposure. This short time course suggests that thapsigargin acts post-translationally to promote the relocation of intracellular protein to the membrane surface and that changes in gene expression are not essential.
Pharmacological Rescue Requires the Golgi Apparatus for Surface Expression of G601S
Complex glycosylation, or the generation of the 155kD protein band on Western blot, is a hallmark of HERG protein maturation and pharmacological rescue (2, 5, 6).
The immunocytochemical and confocal imaging results support this; pharmacological rescue redistributed G601S protein from predominantly peri-nuclear intracellular compartment(s) to the cytoplasm and surface membrane. Furthermore, disrupting the Golgi apparatus using BFA prevented rescue of I G601S . We conclude that the G601S mutation is 'trapped' within an intracellular compartment, presumably the ER (1,6), and that pharmacological rescue of the G601S channel protein with both thapsigargin and E4031 requires an intact Golgi apparatus for complex glycosylation and subsequent transport into the surface membrane. Taken together, our data suggest that thapsigaraninduced and E4031-induced pharmacological rescue of G601 channels follow a similar pathway to the surface membrane. In contrast, brief disruption of the Golgi apparatus by BFA had no effect on WT I HERG .
In summary, these findings show that thapsigargin selectively rescues the G601S and F805C, but not the N470D LQT2 mutant channels. Thapsigargin-induced rescue does not involve HERG channel block, thus these experiments uncouple HERG channel block from pharmacological rescue. Although thapsigargin also rescues the ∆F508 mutation in CFTR, the mechanisms for pharmacological rescue appear to be different for these two channel types and therefore may not involve common molecular chaperone Page 16/r1 proteins or processing checkpoints. Furthermore, given the differences in the pharmacological rescue of N470D, G601S, and F805C, we suggest that trafficking of these mutations is differentially regulated and that multiple rescue pathways may exist.
A more detailed understanding of pharmacological rescue in LQT2 trafficking defective mutations is needed. Although not directly clinically applicable, these findings provide new information about potential pathways that may be exploited to develop new therapies for diseases caused by proteins with trafficking defects. Thapsigargin increased the absolute mean peak tail I G601S density in a time dependent manner compared to control (Con) cells (*, p<0.05). C. Western blot analysis showed that the mature protein band was detectable 3 hours after incubating the cells in 5µM E4031 or 1µM thapsigargin (Thapsi) compared to control (Con). 
